Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SYBX | US
-0.02
-1.39%
Healthcare
Biotechnology
30/06/2024
17/10/2024
1.42
1.45
1.45
1.40
Synlogic Inc. a clinical-stage biopharmaceutical company engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618 an orally administered non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934 an orally administered non-systemically absorbed drug candidate which is in Phase III clinical trial to treat phenylketonuria; SYNB1353 an orally administered non-systemically absorbed drug candidate which is in Phase II clinical to treat homocystinuria; SYNB8802 an orally administered non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891 an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks Inc. Synlogic Inc. is based in Cambridge Massachusetts.
View LessValue Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
29.1%1 month
68.8%3 months
52.3%6 months
46.1%-
-
1.02
-
-
0.18
0.35
-
-36.00M
16.61M
16.61M
-
-1.17K
-
-95.40
-158.75
5.16
1.36
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.16
Range1M
0.30
Range3M
0.53
Rel. volume
0.83
Price X volume
12.89K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Minerva Neurosciences Inc | NERV | Biotechnology | 2.58 | 18.04M | -3.37% | n/a | -194.60% |
Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 0.4456 | 17.88M | -0.49% | n/a | 2.71% |
Inhibikase Therapeutics Inc. | IKT | Biotechnology | 2.35 | 17.54M | 21.13% | n/a | 3.49% |
Kazia Therapeutics Limited | KZIA | Biotechnology | 0.5269 | 17.54M | 58.04% | n/a | 6.82% |
Athira Pharma Inc | ATHA | Biotechnology | 0.4477 | 17.21M | -1.52% | n/a | 1.69% |
GeoVax Labs Inc | GOVX | Biotechnology | 2.01 | 17.15M | -4.29% | n/a | -6.03% |
ICU | ICU | Biotechnology | 4.02 | 16.85M | -4.29% | n/a | -45.50% |
IN8bio Inc. Common Stock | INAB | Biotechnology | 0.2301 | 16.69M | 0.52% | n/a | 43.30% |
Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.7 | 16.46M | 0.00% | n/a | 0.64% |
Evaxion Biotech A/S | EVAX | Biotechnology | 2.71 | 15.99M | 0.00% | n/a | 837.11% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.18 | 0.53 | Cheaper |
Ent. to Revenue | 0.35 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 1.02 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 52.27 | 72.92 | Lower Risk |
Debt to Equity | - | -1.24 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 16.61M | 3.78B | Emerging |